SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02403193

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Phase I/Ib Trial of Single Agent PBF-509 and in Combination With PDR001 for Patients With Advanced NSCLC

The purpose of this study is to determine the safety, tolerability, feasibility and preliminary efficacy of the administration of PBF-509 (Adenosine A2a receptor antagonist) as single agent or in combination with PDR001 (programmed cell death 1 receptor antibody (PD-1 Ab)) to NSCLC patients.

NCT02403193 Non-small Cell Lung Cancer (NSCLC)
MeSH: Lung Neoplasms Carcinoma, Non-Small-Cell Lung
HPO: Neoplasm of the lung Non-small cell lung carcinoma

9 Interventions

Name: PBF-509_80 mg

Description: PBF-509: 80 mg, PO, twice daily (BID)

Type: Drug

PBF-509_80 mg

Name: PBF-509_160 mg

Description: PBF-509: 160 mg, PO, twice daily (BID)

Type: Drug

PBF-509_160 mg

Name: PBF-509_320 mg

Description: PBF-509: 320 mg, PO, twice daily (BID)

Type: Drug

PBF-509_320 mg

Name: PBF-509_640 mg

Description: PBF-509: 640 mg, PO, twice daily (BID)

Type: Drug

PBF-509_640 mg

Name: Combo PBF-509 (160 mg) + PDR001

Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally

Type: Drug

PBF509_160 mg +PDR001

Name: Combo PBF-509 (320 mg) + PDR001

Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally

Type: Drug

PBF509_320 mg+PDR001

Name: Combo PBF-509 (640 mg) + PDR001

Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally

Type: Drug

PBF509_640 mg +PDR001

Name: RP2D (PBF-509+PDR001)_immuno naïve

Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally

Type: Drug

RP2D (PBF-509+PDR001)_immuno naïve

Name: Experimental: RP2D (PBF-509+PDR001)_immuno treated

Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally

Type: Drug

RP2D (PBF-509+PDR001)_immuno treated


Primary Outcomes

Description: The MTD evaluation will be based on the DLT Evaluable Population which includes all patients enrolled in the dose-escalation portion of the trial, who receive the protocol-assigned treatment with PBF-509 and complete the safety follow-up through the DLT evaluation period, or experience a DLT during the DLT evaluation period.

Measure: Maximum Tolerated Dose (MTD) of PBF-509 as single agent

Time: 28 days

Description: The MTD evaluation will be based on the DLT Evaluable Population which includes all patients enrolled in the dose-escalation portion of the trial, who receive the protocol-assigned treatment with PDR001 and PBF-509 and complete the safety follow-up through the DLT evaluation period, or experience a DLT during the DLT evaluation period.

Measure: Maximum Tolerated Dose (MTD) of the combination (PBF-509+PDR001) treatment

Time: 56 days

Secondary Outcomes

Description: The parameter will be calculated from plasma samples collected at days 1 and 8 after drug administration. It will consist in the time (in minutes) to reach the maximum "PBF-509" concentration in plasma samples of patients after oral administration of PBF-509.

Measure: Time to PBF-509 peak concentration in plasma "Tmax"

Time: 8 days

Description: The parameter will be calculated from plasma samples collected at days 1 and 8 after drug administration. It will consist in the time (in minutes) to reach the maximum "PBF-509" concentration in plasma samples of patients during a dosing interval at steady state.

Measure: Time to PBF-509 peak concentration in plasma at steady state "Tmax,ss"

Time: 8 days

Description: The parameter will be calculated from plasma samples collected at days 1 and 8 after drug administration. It will consist in the maximum plasma concentration (ng/mL) of PBF-509 observed after administration.

Measure: PBF-509 peak concentration in plasma "Cmax"

Time: 8 days

Description: The parameter will be calculated from plasma samples collected at days 1 and 8 after drug administration. It will consist in the maximum plasma concentration (ng/mL) of PBF-509 observed during a dosing interval at steady state.

Measure: PBF-509 peak concentration in plasma at steady state"Cmax,ss"

Time: 8 days

Description: The parameter will be calculated from plasma samples collected at days 1 and 8 after drug administration. It will consist in the area under the concentration-time curve from zero up to ∞ with extrapolation of the terminal phase. "AUC(0-inf)" will be given in Amount·time/ volume units

Measure: The area under PBF-509 plasma concentration-time curve to infinite time "AUC(0-inf)"

Time: 8 days

Description: The parameter will be calculated from plasma samples collected at days 1 and 8 after drug administration. It will consist in the area under the concentration-time curve from zero up to a definite time t. "AUC(0-t)" will be given in Amount·time/ volume units.

Measure: The area under PBF-509 plasma concentration-time curve up to time 't' "AUC(0-t)"

Time: 8 days

Description: The parameter will be calculated from plasma samples collected at days 1 and 8 after drug administration. It will consist in the area under the concentration-time curve over the dosing interval. "AUC(0-τ)" will be given in Amount·time/ volume units.

Measure: The area under PBF-509 plasma concentration-time curve over the dosing interval "AUC(0-τ)"

Time: 8 days

Description: The parameter will be calculated from plasma samples collected at days 1 and 8 after drug administration. It will consist in the terminal half-life of PBF-509 in plasma. "t½" will be given in hours (h)

Measure: PBF-509 half-life in plasma " t½"

Time: 8 days

Description: The parameter will be calculated from plasma samples collected at days 1 and 8 after drug administration. It will consist in the apparent volume of distribution during terminal phase after oral / extravascular administration. "Vd/F" will be given in Volume or volume/kg units.

Measure: PBF-509 apparent volume of distribution following extravascular administration"Vd/F"

Time: 8 days

Description: The parameter will be calculated from plasma samples collected at days 1 and 8 after drug administration. It will consist in the apparent total plasma or serum clearance of drug after oral administration. "Cl/F" will be given in the Volume/ time or volume/ time/ kg units.

Measure: PBF-509 total body clearance following extravascular administration "Cl/F"

Time: 8 days

Description: The parameter will be calculated from plasma samples collected at days 1 and 8 after drug administration. It will consist in the accumulation ratio calculated from Cmax,ss at steady state and Cmax after single dosing.

Measure: The PBF 509 accumulation index "Rac"

Time: 8 days

Description: ORR: Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). ORR is defined as confirmed complete response (CR) or partial response (PR) based on modified RECIST v1.1.

Measure: Efficacy as measured by Objective response rate (ORR)

Time: 3 years

Description: The disease control rate (DCR) will be estimated considering the following variables: Complete response (CR), Partial response (PR) and stable disease (SD) as described by Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). These variables will be assessed based on Imaging-based evaluation methods as chest x-ray, conventional computed tomography (CT) and magnetic resonance imaging (MRI) that will be performed every 2 cycles of 28 days administration

Measure: Efficacy as measured by Disease control rate (DCR)

Time: 3 years

Description: Duration of response (DoR) is defined as the duration from the first documentation of OR to the first documented disease progression or death due to any cause, whichever occurs first.

Measure: Efficacy as measured by duration of response (DoR)

Time: 3 years

Description: Progression-free survival (PFS) will be measured from the start of treatment until the documentation of disease progression or death due to any cause, whichever occurs first. For subjects who are alive and progression-free at the time of data cut-off for analysis, PFS will be censored at the last tumor assessment date.

Measure: Efficacy as measured by progression-free survival (PFS)

Time: 3 years

Description: Overall survival (OS) will be determined as the time from the start of treatment until death due to any cause.

Measure: Efficacy as measured by overall survival (OS)

Time: 3 years

Purpose: Treatment

Allocation: Non-Randomized

Single Group Assignment


There is one SNP

SNPs


1 L858R

2. Patients must previously have received at least one prior line of therapy for their disease 3. EGFR mutation with exon 19 deletion or L858R mutation (Exon 21) or ALK rearrangement positive must have failed prior TKI therapy 4. Able, willing to give written consent for available archival tumor samples (not mandatory) and tumor biopsies before and during protocol therapy (mandatory). --- L858R ---



HPO Nodes


HPO:
Neoplasm of the lung
Genes 61
REST GPC3 WT1 HPGD BRAF PIK3CA TP53 TRIM28 RB1 TRIP13 SLCO2A1 AKT1 CASP8 KRAS TSC1 POU6F2 EWSR1 PRKN LMNA NAB2 TERT TSC2 SLC22A18 BRCA2 PPP2R1B STAT6 STK11 MUC5B ERBB2 TSC2 MBTPS2 BAP1 TSC2 DICER1 PDGFRB PERP EGFR TSC1 DIS3L2 NOTCH3 KEAP1 DICER1 DICER1 WT1 TSC1 C11ORF95 IRF1 CYP2A6 WRN RELA WT1 PTEN SFTPC SFTPA2 ERCC6 TRPV3 TP53 H19 TRIM28 FASLG MAP3K8
Non-small cell lung carcinoma
Genes 3
TP53 TP53 BAP1